<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082754</url>
  </required_header>
  <id_info>
    <org_study_id>CSL311_1001</org_study_id>
    <secondary_id>2019-001135-32</secondary_id>
    <nct_id>NCT04082754</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Test the Safety, Exposure, and Markers of Efficacy of CSL311 in Patients With Mild Asthma</brief_title>
  <official_title>A Phase 1, First-in-human, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL311 in Subjects With Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, first-in-human (FIH), multi-center, randomized, double-blind,
      placebo-controlled study of CSL311 in patients with mild asthma. The primary objective of
      this study is to assess the safety and tolerability of single ascending doses (SAD) and
      multiple ascending doses (MAD) of CSL311.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with treatment-emergent adverse events (TEAEs) in single ascending doses (SAD)</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with treatment-emergent adverse events (TEAEs) in multiple ascending doses (MAD)</measure>
    <time_frame>Up to 17 weeks after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with related TEAEs in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with related TEAEs in MAD</measure>
    <time_frame>Up to 17 weeks after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with TEAEs by severity in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
    <description>Severity of TEAEs defined as mild, moderate, or severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with TEAEs by severity in MAD</measure>
    <time_frame>Up to 17 weeks after infusion</time_frame>
    <description>Severity of TEAEs defined as mild, moderate, or severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of CSL311 in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax) of CSL311 in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to the last measurable concentration (AUC0-last) of CSL311 in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 extrapolated to infinite time (AUC0-inf) of CSL311 in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t½) of CSL311 in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of CSL311 in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) of CSL311 in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to the last measurable concentration per dose of CSL311 (AUC0-last/dose) in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax/dose of CSL311 in SAD</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau for CSL311 in MAD after first dose</measure>
    <time_frame>Up to 15 days after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau/dose for CSL311 in MAD after first dose</measure>
    <time_frame>Up to 15 days after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax/dose of CSL311 in MAD after first dose</measure>
    <time_frame>Up to 15 days after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax/dose of CSL311 in MAD after first dose</measure>
    <time_frame>Up to 15 days after infusion</time_frame>
    <description>Dose-normalized maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of CSL311 in MAD after first dose</measure>
    <time_frame>Up to 15 days after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CSL311 in MAD after last dose</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau for CSL311 in MAD after last dose</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax/dose of CSL311 in MAD after last dose</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of CSL311 in MAD after last dose</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau/dose for CSL311 in MAD after last dose</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
    <description>Dose-normalized area under the concentration-time curve over a dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t½) of CSL311 in MAD after last dose</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of CSL311 in MAD after last dose</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) of CSL311 in MAD after last dose</measure>
    <time_frame>Up to 13 weeks after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with detectable anti-CSL311 antibodies in SAD and MAD</measure>
    <time_frame>Up to 13 weeks after infusion for SAD and up to 17 after infusion weeks for MAD</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with TEAEs of Infections and Infestations in SAD and MAD by treatment (CSL311 or placebo), by causality, and by CSL311 dose level</measure>
    <time_frame>Up to 13 weeks after infusion for SAD and up to 17 after infusion weeks for MAD</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with severe or life-threatening Neutropenia in SAD and MAD by treatment (CSL311 or placebo), by causality, and by CSL311 dose level</measure>
    <time_frame>Up to 13 weeks after infusion for SAD and up to 17 weeks after infusion for MAD</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with TEAEs of Worsening Asthma in SAD and MAD by treatment (CSL311 or placebo), by causality, and by CSL311 dose level</measure>
    <time_frame>Up to 13 weeks after infusion for SAD and up to 17 weeks after infusion for MAD</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CSL311 Cohort A1 (SAD Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a Single Ascending Dose (SAD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort A2 (SAD Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort A3 (SAD Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort A4 (SAD Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort A5 (SAD Dose 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort A6 (SAD Dose 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort A7 (SAD Dose 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort A8 (SAD Dose 8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort B1 (MAD Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort B1 (MAD Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort B1 (MAD Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL311 Cohort B1 (MAD Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride solution administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human beta common receptor antagonist monoclonal antibody</intervention_name>
    <description>Human beta common receptor antagonist monoclonal antibody administered intravenously</description>
    <arm_group_label>CSL311 Cohort A1 (SAD Dose 1)</arm_group_label>
    <arm_group_label>CSL311 Cohort A2 (SAD Dose 2)</arm_group_label>
    <arm_group_label>CSL311 Cohort A3 (SAD Dose 3)</arm_group_label>
    <arm_group_label>CSL311 Cohort A4 (SAD Dose 4)</arm_group_label>
    <arm_group_label>CSL311 Cohort A5 (SAD Dose 5)</arm_group_label>
    <arm_group_label>CSL311 Cohort A6 (SAD Dose 6)</arm_group_label>
    <arm_group_label>CSL311 Cohort A7 (SAD Dose 7)</arm_group_label>
    <arm_group_label>CSL311 Cohort A8 (SAD Dose 8)</arm_group_label>
    <arm_group_label>CSL311 Cohort B1 (MAD Dose 1)</arm_group_label>
    <arm_group_label>CSL311 Cohort B1 (MAD Dose 2)</arm_group_label>
    <arm_group_label>CSL311 Cohort B1 (MAD Dose 3)</arm_group_label>
    <arm_group_label>CSL311 Cohort B1 (MAD Dose 4)</arm_group_label>
    <other_name>CSL311</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride, same volume and same duration as CSL311, administered intravenously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects 18 to 65 years of age with diagnosis of mild asthma

        Exclusion Criteria:

          -  Oral/parenteral corticosteroids, anti-interleukin-5 therapy, or live-attenuated
             vaccines within 6 months before screening.

          -  History or presence of clinically significant hypertension or other significant
             cardiovascular abnormality.

          -  Any clinically significant abnormality on electrocardiogram at screening.

          -  Parasitic infestation within 6 months before screening, or travel or intention to
             travel to a country with a high prevalence of such infections within 1 year before
             screening or within 85 days after the last dose of CSL311.

          -  Occurrence of asthma exacerbation and/or upper/lower respiratory tract infection, or
             any acute infection or disease within the last 6 weeks before screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.</ipd_time_frame>
    <ipd_access_criteria>Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

